{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'hormonal contraceptive: oral contraceptive pill (estrogen/progestin pill or', 'progestin-only pill), contraceptive skin patch, vaginal contraceptive ring, or', 'subcutaneous contraceptive injection', 'Subjects should be informed that taking the study medication may involve unknown risks', 'to the fetus (unborn baby) if pregnancy were to occur during the study. In order to', 'participate in the study subjects of childbearing potential must adhere to the contraception', 'requirement (described above) from the day of study medication initiation (or 14 days prior', 'to the initiation of study medication for oral contraception) throughout the study period up', 'to 3 months for males after the last dose of trial therapy. If there is any question that a', 'subject of childbearing potential will not reliably comply with the requirements for', 'contraception, that subject should not be entered into the study.', 'Page 27 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '9', 'STUDY CALENDAR', 'Months (+/-4 days)', 'Progression11', 'Protocol Procedures', 'Screening\u00b9', 'M0', 'M3', 'M6', 'M9', 'M12', 'M18', '(Day 1)', 'Informed Consent', 'X', 'Inclusion/Exclusion Criteria', 'X', 'Vital Signs', 'X2', 'Physical Exam with ECOG', 'X', 'Complete Blood Count (CBC) with Platelet Count, Differential', 'X', 'Comprehensive Metabolic Panel (CMP)', 'X', 'Urinalysis', 'X', 'Testosterone', 'X', 'PSA', 'X8', 'X', 'X', 'X', 'X', 'CT - Chest/Abdomen/Pelvis10', 'X', 'X\u00b3', 'X', 'Whole Body Bone Scan', 'X', 'X', 'Archival Tissue Submission (if available)', 'X4', 'Fresh Tissue Collection', 'Correlative Blood Collection6', 'X8', 'X', 'X', 'ADT + Docetaxel or ADT + Abiraterone', 'Questionnaires - FACT P, FACT/GOG-NTX, PROMIS Fatigue', 'X8', 'X', 'X', 'X', 'Adverse Event Collection13', 'X', 'X', 'Medical History', 'X', 'Exploratory Questionnaires\u00b92', 'X', 'X', 'Extent of Metastases Form (Appendix 1)', 'X', 'Note: All visits will be based on treatment start date and will be performed independent of treatment cycles and/or delays. 1', 'month will be defined as 28 days.', 'Page 28 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '1) Screening procedures should be performed within 28 days of Day 1 (Treatment initiation). There is no window designated for the screening diagnostic', 'CT and/or bone scan prior to study enrollment.', '2)', 'Vitals include height, weight, blood pressure, pulse, and temperature.', '3) To be repeated per clinical indication.', '4) To be performed prior M3 visit.', '5)', 'If the patient has consented to optional tissue collection, tissue may be collected from any SOC biopsy performed while on trial or at the end of treatment', '(month 18 or progression visit, whichever comes first).', '6)', 'If the patient consents to optional blood collection, blood will be collected at month 0 (prior to treatment), month 3, month 6 and the end of treatment', '(month 18 or progression visit, whichever comes first).', '7) Treatment length will depend on randomization assignment. Arm A will receive ADT + Docetaxel IV approximately Q3weeks x 6 cycles. Arm B will', 'receive ADT + Abiraterone PO (per drug-specific dosing guidelines), unless there is disease progression.', '8) To be performed prior to treatment initiation on Day 1. If treatment initiation is delayed by >4 days after completion of baseline questionnaires, these', 'should be repeated.', '9) Testosterone should be monitored monthly, or per institutional standard of care, to confirm castrate level testosterone concentration (i.e. total', 'testosterone V 50 ng/dL).', '10) Imaging techniques and sequences should be performed per institutional standard of care. Axumin PET CT Skull Base to Mid-Thigh', 'will', 'be', 'allowed', 'at screening.', '11) Procedures required at the time of progression will be performed within +/- 30 days of diagnosis of progression. Diagnosis of progression is per the', 'discretion of the treating physician. The protocol suggests defining progression based on radiographic or clinical progression and not PSA only', 'progression.', '12) The Overall Treatment Utility (OTU) form, Was It Worth It (WIWI) questionnaire, and End of Study Evaluation Form will be administered to patients', 'for', 'exploratory', \"purposes. The OTU for should be completed by the treating physician at the patient's 3 month visit and the WIWI questionnaire and\", 'End of Study Evaluation Form administered to the patient at the end of treatment (month 18 or progression visit, whichever comes first).', '13) Due to extensive characterization of study treatment regimens through previous clinical trials and in the standard clinical context, adverse event', 'collection will be limited in scope and occur in accordance with recording and reporting guidelines set forth in Section 16.2.', 'Page 29 of 52']\n\n###\n\n", "completion": "END"}